Celgene Co. (NASDAQ:CELG) Director Ernest Mario sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the transaction, the director now owns 44,413 shares in the company, valued at approximately $4,100,208.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ CELG traded up $0.75 on Monday, hitting $91.96. 429,605 shares of the stock were exchanged, compared to its average volume of 5,657,379. Celgene Co. has a 52-week low of $74.13 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 5.76, a quick ratio of 1.40 and a current ratio of 1.52. The stock has a market cap of $64.15 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 0.57 and a beta of 1.32.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.05. Celgene had a net margin of 19.81% and a return on equity of 87.28%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.70 billion. During the same period in the previous year, the company posted $1.82 EPS. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. research analysts forecast that Celgene Co. will post 7.64 EPS for the current fiscal year.

Celgene declared that its board has authorized a stock repurchase program on Thursday, May 24th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 5.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

CELG has been the topic of several recent research reports. Sanford C. Bernstein upgraded shares of Celgene from a “market perform” rating to an “outperform” rating and set a $102.00 price target on the stock in a research report on Wednesday, May 23rd. Credit Suisse Group set a $129.00 price target on shares of Celgene and gave the stock a “buy” rating in a research report on Saturday, May 5th. Zacks Investment Research lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th. Morgan Stanley decreased their price target on shares of Celgene from $93.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Monday, May 7th. Finally, Leerink Swann restated a “buy” rating and issued a $115.00 price target (down previously from $123.00) on shares of Celgene in a research report on Monday, May 7th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twenty have given a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $121.85.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Guggenheim Capital LLC boosted its stake in shares of Celgene by 1.9% during the 4th quarter. Guggenheim Capital LLC now owns 1,047,769 shares of the biopharmaceutical company’s stock valued at $109,348,000 after buying an additional 19,218 shares during the period. Kendall Capital Management acquired a new stake in shares of Celgene during the 4th quarter valued at $300,000. Ellington Management Group LLC boosted its stake in shares of Celgene by 136.2% during the 4th quarter. Ellington Management Group LLC now owns 13,700 shares of the biopharmaceutical company’s stock valued at $1,430,000 after buying an additional 7,900 shares during the period. Morgens Waterfall Vintiadis & Co. Inc. boosted its stake in shares of Celgene by 35.7% during the 4th quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 19,000 shares of the biopharmaceutical company’s stock valued at $1,983,000 after buying an additional 5,000 shares during the period. Finally, Premia Global Advisors LLC acquired a new stake in shares of Celgene during the 4th quarter valued at $240,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.